The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This will be an added advantage for Supriya Lifescience Limited in the European market.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
Subscribe To Our Newsletter & Stay Updated
